Initial digest — CHRNA7 receipt

what this node claims

Initial digest — CHRNA7

AlphaFold v6 prediction landed for **CHRNA7** (Alpha-7 nicotinic acetylcholine receptor). UniProt accession: `P36544`. Lane: `cognitive`. Mean per-residue pLDDT: **78.33**. PAM design wedge to avoid desensitization.

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

78.3

502 residues / min 28.12 / max 96.94 / source alphafold db

Very high 38.4% 193 residues / >=90

Confident 38.2% 192 residues / 70-89

Low 7.4% 37 residues / 50-69

Very low 15.9% 80 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 502 of 502 residues.

residues 346-430 / mean 37.37
residues 1-21 / mean 57.58
residues 322-325 / mean 68.91
residues 500-502 / mean 62.88

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — CHRNA7